跳至主要内容
临床试验/NCT02770131
NCT02770131已完成不适用

Observational Serial Chart Review of Repatha® Use in European Subjects With Hyperlipidaemia

Amgen1 个研究点 分布在 1 个国家目标入组 1,986 人开始时间: 2016年5月4日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Amgen
入组人数
1,986
试验地点
1
主要终点
Description of clinical characteristics of subjects initiated on Repatha®

研究概览

简要总结

Review of clinical characteristics of patients who are prescribed Repatha® and how their treatment is managed.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults (>18 years) Provided informed consent Initiated on Repatha® at physician's discretion, after 1st August 2015 Received at least one dose of Repatha®

排除标准

  • Enrolled in an interventional study of PCSK9 inhibitor within 12 weeks prior to initiation of Repatha® Received commercially available PCSK9 inhibitor within 12 weeks prior to initiation of Repatha®

结局指标

主要结局

Description of clinical characteristics of subjects initiated on Repatha®

时间窗: Study day 1

Age at initiation of Repatha®, Gender Familial hypercholesterolaemia status Diabetic status, Cardiovascular history History of statin intolerance

次要结局

  • Describe Repatha® dose over time(From the first dose of Repatha® up to 30 months post first dose)
  • Describe hospitalizations(From the first dose of Repatha® up to 30 months post first dose)
  • Describe Repatha® administrative device use over time(From the first dose of Repatha® up to 30 months post first dose)
  • Describe LDL-C and other cholesterol values over time(Up to 26 weeks prior to the first dose of Repatha®, up to 30 months post first dose of Repatha®)
  • Describe use of other lipid-modifying therapies(From the first dose of Repatha® up to 30 months post first dose)
  • Describe Physician visits(From the first dose of Repatha® up to 30 months post first dose)
  • Describe Repatha® dose frequency over time(From the first dose of Repatha® up to 30 months post first dose)

研究者

发起方
Amgen
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验